Dicerna Pharmaceuticals Inc. (DRNA) Trading Down 2.8%
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares traded down 2.8% during mid-day trading on Thursday . The stock traded as low as $3.45 and last traded at $3.49, with a volume of 244,056 shares changing hands. The stock had previously closed at $3.59.
Several research analysts have recently issued reports on the stock. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. Chardan Capital decreased their price target on shares of Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, June 30th. Stifel Nicolaus decreased their price target on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, June 30th. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. Finally, Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research note on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Dicerna Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $11.95.
The company has a 50-day moving average price of $3.48 and a 200 day moving average price of $5.47. The stock’s market capitalization is $72.13 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. Analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current year.
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.